Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BZY9
UPID:
TRI31_HUMAN
Alternative names:
Tripartite motif-containing protein 31
Alternative UPACC:
Q9BZY9; A6NLX6; A9R9Q4; Q53H52; Q5RI37; Q5SRJ7; Q5SRJ8; Q5SS28; Q96AK4; Q96AP8; Q99579; Q9BZY8
Background:
E3 ubiquitin-protein ligase TRIM31, also known as Tripartite motif-containing protein 31, plays a pivotal role in the immune response to viral infections. It regulates antiviral defense by mediating 'Lys-63'-linked ubiquitination of MAVS, enhancing MAVS polymerization on mitochondria. Additionally, TRIM31 acts as a negative regulator of the NLRP3 inflammasome through 'Lys-48'-linked ubiquitination, leading to NLRP3 degradation.
Therapeutic significance:
Understanding the role of E3 ubiquitin-protein ligase TRIM31 could open doors to potential therapeutic strategies. Its involvement in regulating antiviral immune responses and inflammation highlights its potential as a target for developing treatments for viral infections and inflammatory conditions.